Drug
Zw25
Zw25: highest development phase Phase 2, developed by Jazz Pharmaceuticals, Zymeworks. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jazz Pharmaceuticals, Zymeworks
Trials
| Drug | Phase | Indication |
|---|---|---|
| ZW25 (Zanidatamab) NCT04466891 | Phase 2 | HER2-amplified Biliary Tract Cancers |
| ZW25 NCT04513665 | Phase 2 | Endometrial Cancer |
| ZW25 (Zanidatamab) NCT03929666 | Phase 2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
Latest
No recent events.
Follow Zw25 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.